News

Indoco Remedies Limited announced it executed a deed of conveyance on August 27, 2026, to sell a plot of land measuring approximately 2,876.08 square meters to Kalpataru Townships Private Limited for Rs 64,00,00,000. The company stated the sale will not impact its business operations and does not constitute a substantial undertaking, and that no related parties are involved.

Indoco Remedies Limited has fixed Thursday, September 10, 2026, as the record date for determining entitlement to a final dividend of Rs 0.20 per equity share for the financial year ended March 31, 2026, subject to shareholder approval at the Annual General Meeting scheduled for September 17, 2026; the company’s register of members and share transfer books will remain closed from September 11, 2026, to September 17, 2026, and Thursday, September 10, 2026, is also the cut-off date for remote e-voting and e-voting during the AGM.

Net profit of Indoco Remedies reported to Rs 64.99 crore in the quarter ended June 2026 as against net loss of Rs 35.79 crore during the previous quarter ended June 2025. Sales rose 8.21% to Rs 466.22 crore in the quarter ended June 2026 as against Rs 430.86 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales466.22430.86 8 OPM %8.804.07 - PBDT14.91-6.96 LP PBT-19.62-36.66 46 NP64.99-35.79 LP Powered by Capital Market - Live News

Indoco Remedies will hold a meeting of the Board of Directors of the Company on 28 July 2026.

Indoco Remedies announced that Malta Medicines Authority had inspected Company`s manufacturing facility for solid oral dosage form (Plant I) located at Goa (Facility), from 19 November to 24 November 2025. The Facility has received EU GMP certification from the Malta Medicines Authority confirming that the Facility complies with the Good Manufacturing Practice requirements as referred in the EC Directive.